Arch Biopartners Inc ACHFF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHFF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.08
- Day Range
- $1.07–1.14
- 52-Week Range
- $0.72–1.88
- Bid/Ask
- $1.05 / $1.20
- Market Cap
- $72.79 Mil
- Volume/Avg
- 4,500 / 12,081
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.archbiopartners.com
Comparables
Valuation
|
Metric
|
ACHFF
|
NYKD
|
TLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 152.11 |
Price/Book Value | — | 2.79 | 42.00 |
Price/Sales | — | 40.25 | 12.42 |
Price/Cash Flow | — | — | 258.19 |
Price/Earnings
ACHFF
NYKD
TLX
Financial Strength
|
Metric
|
ACHFF
|
NYKD
|
TLX
|
|---|---|---|---|
Quick Ratio | 0.23 | 8.43 | 1.19 |
Current Ratio | 0.23 | 8.43 | 1.43 |
Interest Coverage | −4.45 | — | 1.15 |
Quick Ratio
ACHFF
NYKD
TLX
Profitability
|
Metric
|
ACHFF
|
NYKD
|
TLX
|
|---|---|---|---|
Return on Assets (Normalized) | −74.91% | −18.26% | 3.71% |
Return on Equity (Normalized) | — | −23.64% | 11.73% |
Return on Invested Capital (Normalized) | — | −26.98% | 18.08% |
Return on Assets
ACHFF
NYKD
TLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Lvrthtklj | Pmdc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mxpnfkp | Xhvzhs | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pyfsnyhn | Mrdnbx | $118.7 Bil | |||
| Moderna Inc
MRNA
| Zfqrjzcmc | Fjvf | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vzghfgjw | Kgclktr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Jgrzrgbwq | Vbqq | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Dslyghnp | Cysh | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Prglbjc | Qfvknby | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Zlltjdwt | Wfck | $15.0 Bil | |||
| Incyte Corp
INCY
| Qztwgpnn | Jnlxkb | $13.5 Bil |